Renaissance Technologies LLC Has $1.51 Million Stock Holdings in Shattuck Labs, Inc. (NASDAQ:STTK)

Renaissance Technologies LLC raised its stake in shares of Shattuck Labs, Inc. (NASDAQ:STTK) by 83.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 392,010 shares of the company’s stock after buying an additional 177,910 shares during the period. Renaissance Technologies LLC’s holdings in Shattuck Labs were worth $1,513,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of STTK. Cannon Global Investment Management LLC acquired a new stake in Shattuck Labs during the first quarter valued at $91,000. Virtu Financial LLC acquired a new stake in shares of Shattuck Labs during the 1st quarter valued at about $113,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Shattuck Labs during the 1st quarter valued at about $174,000. SG Americas Securities LLC grew its stake in shares of Shattuck Labs by 4.8% in the 1st quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock valued at $352,000 after buying an additional 1,788 shares in the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Shattuck Labs in the second quarter worth approximately $170,000. 58.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

STTK has been the subject of several recent research reports. BTIG Research downgraded shares of Shattuck Labs from a “buy” rating to a “neutral” rating in a research report on Monday, June 17th. Evercore ISI raised shares of Shattuck Labs to a “strong-buy” rating in a research report on Wednesday. HC Wainwright cut Shattuck Labs from a “buy” rating to a “neutral” rating in a research report on Tuesday. Citigroup downgraded Shattuck Labs from a “buy” rating to a “neutral” rating and cut their price objective for the company from $8.00 to $2.00 in a research note on Wednesday. Finally, Needham & Company LLC cut Shattuck Labs from a “buy” rating to a “hold” rating and set a $8.00 target price for the company. in a research report on Wednesday. Four research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Shattuck Labs presently has a consensus rating of “Hold” and a consensus target price of $8.67.

Shattuck Labs Price Performance

Shattuck Labs stock opened at $1.22 on Friday. The firm has a market cap of $58.01 million, a price-to-earnings ratio of -0.63 and a beta of 1.72. The firm has a fifty day moving average price of $3.43 and a two-hundred day moving average price of $6.01. Shattuck Labs, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $11.76.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, August 1st. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). The business had revenue of $1.61 million for the quarter, compared to the consensus estimate of $0.50 million. Shattuck Labs had a negative net margin of 2,067.99% and a negative return on equity of 68.65%. The business’s revenue for the quarter was up 704.5% on a year-over-year basis. As a group, sell-side analysts expect that Shattuck Labs, Inc. will post -1.72 earnings per share for the current year.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.